https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29616 1000). Conclusion: Although data from randomised clinical trials on the clinical impact of sunitinib TDM are lacking, our findings support implementation of sunitinib TDM in clinical practice. For rare cancers with well-defined exposure–response relationships, modelling and simulation might allow the optimisation of dosing strategies when clinical trials cannot be performed due to low number of patients.]]> Thu 03 Feb 2022 12:18:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14589 Sat 24 Mar 2018 08:20:46 AEDT ]]>